Scholar Rock Holding (SRRK) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Scholar Rock Holding Corporation ( SRRK ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants David Hallal - CEO & Chairman of the Board Conference Call Participants Michael Yee - UBS …

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 39,587 shares of its common stock to six newly hire…

Scholar Rock NASDAQ: SRRK reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular atrophy treatment ISEMBYLD, while executives said insurance and reimbursement hurdles …

Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript…

Scholar Rock Holding Corporation (SRRK) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.9 per share a year ago.…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its l…

Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hi…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its l…

Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) traded down 5.1% on Monday. The stock traded as low as $44.59 and last traded at $44.4380. Approximately 908,652 shares were traded during mid-d…

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary d…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hire…

Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 211.3% during the second quarter, according to the company in its most recent disclosure with the Securities and …

Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD [apitegromab] for SMA in patients ≥2 years old. SRRK targets a $2B+ market opportunity in SMA, with expansion potential …

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript…

The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock (NASDAQ:SRRK) for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older.…

Scholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients with the rare genetic d…

Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children …

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its l…

The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy to treat a rare genetic condition that causes muscle weakness.…

Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to drug efficacy or safety;…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its w…
Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissi…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its w…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

